1Mengshol JA ,Mix KS ,Brinckerhoff CE. Matrix metalloproteinas es astherapeutic targets in arthritic diseases [ J ]. Arthritis and Rheumatism ,2002,46( 1 ) :13.
2Ekbom A. Epedemiology of inflammatory bowel disease. In: Bistrian BR,Walker-Smith JA, editors[ M]. Inflammatory Bowel Diseases.Basel: Karger, 1999,7.
3Loftus Jr EV, Silverstein MD, Sandbom W J. Ulcerative cotitis in Olmsted Country, Minnesota, 1940-1993 ; incidence, prevalence,and survival[ J ]. Gut,2000,46 ( 3 ) :336.
4Von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory, bowel disease [ J ]. Gut, 2000,47(1):63.
5Heuschkel RB, MacDonald TY, Monteleone G, et al. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesion of children with inflammatory bowel disease[ J ]. Gut ,2000,47 ( 1 ) :57.
6Saafialho-kere UK, Vaalamo M, Puolakkainen P, et al. Enhanced expression of matrilysin, and stromclysin-1 in gastrointestinal ulcer[ J ].Am J Pathol,1996,148:519.
7Vaalamo M, Karjalaincn-Lindsbcrg ML, Puolakkaincn P, ct al. Distinct expression profiles of stromclysin-2 ( mmp-10 ), collagcnase-3( MMP-13 ), macrophagc mctalloprotcinase ( MMP-12 ) , and tissue inhibitor of mctalloproteinase-3 (TIMP-3) in intestinal ulceration[J]. Am J Pathol,1998,152:1005.
8Matthes H, Herbst H, Schuppan D, et al. Cellular localization of procollagen gene transcripts in inflammatory bowel diseases[ J]. Gastroenterology, 1992,102:431.
9Gunther U, Schuppan D, Matthes H, et al. Fibrogenesis and fibrolysis in collagenous colitis: patterns of procoUagen type Ⅰ and Ⅳ, matrix metalloproteinase-1 and -13 ,and TIMP-1 gene expression[ J]. Am J Pathol, 1999,155:493.
10Pcndcr SLF, Tickle SP, Dochcrty AJ, ct al. A major role of matrix metalloproycinases in T cell injury in the gut [ J ]. J Immunol, 1997,158: 1582.
同被引文献10
1Morris GP, Beck PL, Herridge MS, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology, 1989,96:795-803.
2Medina C, Videla S, Radomski A, et al. Therapeutic effect of phenanthroline in two rat models of inflammatory bowel disease. Scand J Gastroenterol, 2001,36:1314-1319.
3Park JM, Adam RM, Peters CA, et al. AP-1 mediates stretch-induced expression of HB-EGF in bladder smooth muscle cells. Am J Physiol, 1999, 277 :C294-301.
4Yan M, Schneider J, Gear R, et al. Expression of angiogenic factors is upregulated in DMBA-induced rat mammary pathologies. Pathobiology, 2004, 71:253-260.
5Deschner J, Rath-Deschner B, Agarwal S. Regulation of matrix metalloprot-einase expression by dynamic tensile strain in rat fibrochondrocytes. Osteoart-hritis Cartilage, 2006, 14:264-272.
6Suzuki A, Hanada T, Mitsuyama K, et al. CIS3/SOCS3/SSI3 plays a negativeregulatory role in STAT3 activation and intestinal inflammation. J Exp Med, 2001, 193:471-481.
7Lovato P, Brender C, Agnholt J, et al. Constitutive STAT3 Activation in intestinal T Cells from Patients with Crohn's Disease. J Biol Chem, 2003,278 : 16777-16781.
8Alessandro M, Patrizia D, Alessandra C, et al. Signal transducers and activators of Transcription 3 signaling pathway an essential mediator of Inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis, 2005,11:91-98.
9Yamamoto M, Yoshizaki K, Kishimoto T, et al. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol, 2000, 164:4878-4882
